The European Commission is looking at taking vaccine producer AstraZeneca to court for cutting Covid vaccine deliveries, Ireland’s health minister has confirmed.
The issue was raised during a meeting of EU ambassadors yesterday, “during which the majority of EU countries said they would support suing the company” after “it massively failed to deliver pledged doses to the bloc”, Politico reported last night. One diplomat said the ultimate aim was to ensure that the Cambridge-based company delivered the promised number of doses.
Stephen Donnelly told the Irish parliament today that the legal case had “been initiated” around AstraZeneca’s “complete failure to meet its delivery and contractual agreements for April, May and June”, Sky News reports. However, a European Commission spokesperson told the broadcaster: “The decision to take legal action has not been taken at this point in time.”
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
An EU official told Reuters: “It is about fulfilment of deliveries by the end of the second quarter.”
The bloc signed an agreement with AstraZeneca for the delivery of 300 million vaccines by the end of June, but the pharma giant announced last month that only 70 million would be handed over to the EU27 by that deadline.
The company has come under fire after cutting supplies several times to levels much lower than promised, with the European Commission blaming the “shortfalls in AstraZeneca deliveries for the slow pace of its vaccination rollout”, says The Telegraph.
The newspaper predicted that any legal action would probably come down to a dispute over “breach of contract”, with Brussels accusing AstraZeneca of reneging on its deal amid “suspicions that some EU stock may have gone to Britain or other countries”. AstraZeneca denies the allegations.
A senior EU source said yesterday that the bloc will also not use an option to secure a total 300 million extra doses of AstraZeneca and Johnson & Johnson vaccines that the bloc secured under existing contracts, reports Reuters’ EU correspondent Francesco Guarascio.
The decision is another clear “sign Brussels is looking to distance itself from AstraZeneca”, Guarascio adds, following a public rebuke of the EU from the pharmaceutical company’s CEO in January.
A string of EU countries have suspended the use of the Oxford-AstraZeneca vaccine among some or all age groups amid concerns about rare blood clots.
However, the bloc is pushing to speed up its rollout, with latest Oxford University tracking showing that it has administered 117.8 million vaccines so far - which equates to just 26.49 per 100 people having received at least one dose.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
All about Zealandia, the Earth’s potential 8th continentThe Explainer The secret continent went undiscovered for over 300 years
-
A reckoning over looted art
The Explainer Thousands of artifacts in U.S. and European collections were stolen from their countries of origin. Should they be sent back?
-
A surge in surge pricing
Feature And more of the week's best financial insight
-
What is a 'feminist approach' to cancer care?
The Explainer 800,000 women die from 'preventable' cancers each year due to 'patriarchy', landmark study finds
-
How do we calculate mass deaths?
The Explainer Recent revisions to 9/11, Libyan flood and Covid-19 death tolls raise questions over estimates
-
You can now get a new Covid booster shot. Should you?
Unless you are old or otherwise at high risk, it isn't a 'slam dunk'
-
New Covid variant BA.2.86: does the UK booster programme go far enough?
Talking Point Some MPs and experts say criteria for jabs is ‘too narrow’ ahead of ‘rocky ride’ this winter
-
Covid testing to be ramped up for winter
Speed Read Scientists fear UK could be ‘flying blind’ on infection rates due to lack of monitoring programmes
-
Is it time to mask up again?
Today's Big Question A rise in Covid-19 cases brings back the possibility of mask mandates
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
-
Understanding the new Covid-19 variant, Eris
Speed Read The formally named EG.5 is making the rounds, but we don't have to worry just yet
